Initial proteinuria reduction and adverse kidney outcomes in IgA nephropathy: An analysis from the J-IGACS
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Proteinuria reduction is considered a potential surrogate endpoint predictive of reflecting long-term kidney prognosis in IgA nephropathy (IgAN). However, its association with adverse kidney outcomes and IgAN-related decline in estimated glomerular filtration rate (eGFR) remains uncertain.
Methods
Patients with biopsy-proven IgAN from the Japan IgA Nephropathy Cohort Study (J-IGACS) were analyzed. Participants were categorized into tertiles based on their 12-month proteinuria-to-baseline proteinuria ratios. The primary outcome was a composite of ≥40% eGFR decline or initiation of kidney-replacement therapy. Associations between proteinuria ratio and outcomes were assessed using Cox proportional hazards models and restricted cubic splines. Multivariable analyses adjusted for age, sex, baseline eGFR, log-transformed proteinuria, Oxford classification scores, and use of corticosteroids and renin-angiotensin-aldosterone system inhibitors within 12 months.
Results
Among 793 patients, those in the lowest tertile (greatest proteinuria reduction) had significantly lower risk of the primary endpoint (P for trend <0.001) and a more favorable eGFR slope. Spline analysis showed a continuous, dose-response association between proteinuria ratio and improved outcomes. These findings remained robust in sensitivity analyses restricted to patients likely qualifying for clinical trials. The results showed that patients with lower proteinuria ratios tended to have slower rates of eGFR decline (P for trend <0.001), even after multivariable adjustment.
Conclusion
Proteinuria reduction within the first-year post-diagnosis is independently associated with lower risk of adverse kidney outcomes and a slower decline in kidney function in patients with IgAN. These results support the use of proteinuria reduction as a surrogate endpoint in both clinical trials and disease management.
